RE:RE:RE:RE:RE:RE:RE:RE:Phase 2/3 OV company Genelux trades at US$35.00
Thanks Note for the genelux information. I went to their website and they are actively enrolling in a phase 3 program....This helps show the potential for onc but also is another virus which could be considered direct competition. Their virus basically does exactly what our virus is supposed to do and they are moving ahead quickly at this point.
Olvi-Vec, our lead product candidate, is a modified vaccinia virus that utilizes a triple mode of action: it directly kills cancer cells, stimulates a tumor-specific immune response and converts the tumor microenvironment from an immunosuppressive (cold state) to an immunoreactive (hot state).
I am thinking that onc managment needs to move things along as quickly as possible as the competition is coming along quickly and could keep setting the bar higher as we go.